Here, our aim was to investigate whether patients in the Hungarian melanoma cohort (n = 17) with increased risk carry any pathogenic or likely pathogenic germline variants of the BRCA2, POLE, WRN, FANCI, PALB2, and RAD54B genes associated with melanoma survival and response to therapy. The gene discussed is BRCA2; the disease is melanoma.